BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

22 articles for S Ramurthy

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.EBI
Novartis Institutes For Biomedical Research
Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma.EBI
Novartis Institutes For Biomedical Research
Discovery of Potent and Selective RSK Inhibitors as Biological Probes.EBI
Novartis Institutes For Biomedical Research
Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors.EBI
Novartis Institutes For Biomedical Research
Design and Synthesis of Orally Bioavailable Benzimidazole Reverse Amides as Pan RAF Kinase Inhibitors.EBI
Novartis Institutes For Biomedical Research
2-Amino-7-substituted benzoxazole analogs as potent RSK2 inhibitors.EBI
Novartis Institutes For Biomedical Research
Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors.EBI
Novartis Institutes For Biomedical Research
Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase Activator.EBI
Pharmaron UK Ltd.
4-(Aminoalkylamino)-3-benzimidazole-quinolinones as potent CHK-1 inhibitors.EBI
Chiron
Design and Discovery of EBI
Novartis Institutes For Biomedical Research
Design and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors.EBI
Novartis Institutes For Biomedical Research
Design and synthesis of potent RSK inhibitors.EBI
Novartis Institutes For Biomedical Research
Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3.EBI
Novartis Institutes For Biomedical Research
Combination therapy comprising JAK pathway inhibitor and rock inhibitorBDB
Incyte
Indole derivatives and their use in neurodegenerative diseasesBDB
Merck Patent
Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptorsBDB
Axovant Sciences
Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitorsBDB
Incyte
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of useBDB
Merck Sharp & Dohme
Aggrecanase inhibitorsBDB
Eli Lilly
Exploring the Role of Residue 228 in Substrate and Inhibitor Recognition by VIM Metallo-ß-lactamases.BDB
Louis Stokes Cleveland Veterans Affairs Medical Center
Oxygenation of monoenoic fatty acids by CYP175A1, an orphan cytochrome P450 from Thermus thermophilus HB27.BDB
Tata Institute of Fundamental Research
Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors.BDB
Universitat De Barcelona